{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:53:37Z","timestamp":1760576017665,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.clon.2013.08.009","type":"journal-article","created":{"date-parts":[[2013,9,17]],"date-time":"2013-09-17T03:33:22Z","timestamp":1379388802000},"page":"713-718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Malignant Mesothelioma, Hypoalbuminaemia and the Effect of\u00a0Carboplatin\/Pemetrexed on Survival"],"prefix":"10.1016","volume":"25","author":[{"given":"S.","family":"Murphy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Probert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Clague","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Sridharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2013.08.009_bib1","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2013.08.009_bib2","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1183\/09031936.00168111","article-title":"Mesothelioma incidence projections in South East England","volume":"40","author":"Riaz","year":"2012","journal-title":"Eur Respir J"},{"year":"2012","series-title":"Mesothelioma mortality in Great Britain 1968\u20132010","author":"Health and Safety Executive (HSE)","key":"10.1016\/j.clon.2013.08.009_bib3"},{"key":"10.1016\/j.clon.2013.08.009_bib4","first-page":"ii1","article-title":"British Thoracic Society Standards of Care Committee","volume":"62","author":"BTS Statement on Malignant Mesothelioma in the United Kingdom","year":"2007","journal-title":"Thorax"},{"year":"2011","series-title":"Chemotherapy in Mesothelioma Project ChiMP, Mesothelioma, UK","author":"Peake","key":"10.1016\/j.clon.2013.08.009_bib5"},{"issue":"Issue 1","key":"10.1016\/j.clon.2013.08.009_bib6","article-title":"Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma (Review)","author":"Green","year":"2009","journal-title":"The Cochrane Library"},{"year":"2008","series-title":"Pemetrexed for treatment of malignant from pleural mesothelioma. NICE technology appraisal guidance 135","author":"National Institute for Health and Clinical Excellence","key":"10.1016\/j.clon.2013.08.009_bib7"},{"key":"10.1016\/j.clon.2013.08.009_bib8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.clon.2013.08.009_bib9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clon.2013.08.009_bib10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"issue":"3\/4","key":"10.1016\/j.clon.2013.08.009_bib11","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/sj.bjc.6690105","article-title":"The European mesothelioma epidemic","volume":"79","author":"Peto","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2013.08.009_bib12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/thx.2007.081430","article-title":"Population based epidemiology and prognosis of mesothelioma in Leeds, UK","volume":"63","author":"Chapman","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.clon.2013.08.009_bib13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/thx.52.6.507","article-title":"Malignant mesothelioma in south east England: clinicopathological experience of 272 cases","volume":"52","author":"Yates","year":"1997","journal-title":"Thorax"},{"key":"10.1016\/j.clon.2013.08.009_bib14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1183\/09031936.00153611","article-title":"Population-based survival for malignant mesothelioma after introduction of novel chemotherapy","volume":"40","author":"Damhuis","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clon.2013.08.009_bib15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ijc.23874","article-title":"Survival of pleural malignant mesothelioma in Italy: a population-based study","volume":"124","author":"Montanaro","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clon.2013.08.009_bib16","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1183\/09031936.00000811","article-title":"Predicting survival in malignant mesothelioma","volume":"38","author":"Musk","year":"2011","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.clon.2013.08.009_bib17","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/JTO.0b013e3181e95cb8","article-title":"Prognostic factors for survival after surgical palliation of malignant pleural effusion","volume":"5","author":"Pilling","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2013.08.009_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0003-4975(02)03599-3","article-title":"Early and late mortality after pleurodesis for malignant pleural effusion","volume":"4","author":"Bernard","year":"2002","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.clon.2013.08.009_bib19","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjc.6601242","article-title":"Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small cell lung cancer","volume":"89","author":"Forrest","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2013.08.009_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with plural mesothelioma, the European Organisation for Research and Treatment of Cancer Experience","volume":"16","author":"Curran","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.clon.2013.08.009_bib21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2478\/v10019-012-0032-0","article-title":"Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patients","volume":"46","author":"Kovac","year":"2012","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.clon.2013.08.009_bib22","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","article-title":"Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial","volume":"371","author":"Muers","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2013.08.009_bib23","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.clon.2013.08.009_bib24","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1200\/JCO.2002.10.073","article-title":"Phase 1 clinical and pharmacokinetic study of premetrexed and carboplatin in patients with malignant plural mesothelioma","volume":"20","author":"Hughes","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2013.08.009_bib25","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655513003270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655513003270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:39:26Z","timestamp":1760542766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655513003270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0936655513003270"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2013.08.009","relation":{},"ISSN":["0936-6555"],"issn-type":[{"type":"print","value":"0936-6555"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignant Mesothelioma, Hypoalbuminaemia and the Effect of\u00a0Carboplatin\/Pemetrexed on Survival","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2013.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}